NCT02923466View on ClinicalTrials.gov

Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

April 17, 2017

Primary Completion Date

February 5, 2022

Study Completion Date

April 22, 2022

Conditions
Malignant Solid Tumour
Interventions
BIOLOGICAL

VSV-IFNβ-NIS

Intratumoral injection of a single dose of VSV-IFNβ-NIS

BIOLOGICAL

VSV-IFNβ-NIS and avelumab

Intratumoral injection of a single dose of VSV-IFNβ-NIS and intravenous infusion of avelumab

Trial Locations (6)

33136

University of Miami, Miami

37203

Sarah Cannon Research Institute, Nashville

55455

Masonic Cancer Center, University of Minnesota, Minneapolis

57104

Sanford Cancer Center, Sioux Falls

75230

Mary Crowley Cancer Research Center, Dallas

43205/2664

Nationwide Children's Hospital, Columbus

All Listed Sponsors
lead

Vyriad, Inc.

INDUSTRY

NCT02923466 - Ph1 Administration of VSV-IFNβ-NIS Monotherapy and in Combination With Avelumab in Pts With Refractory Solid Tumors | Biotech Hunter | Biotech Hunter